Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Breast Cancer Stage Clinical Trial

Official title: A Real-world Study of Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Status Not yet recruiting

Clinical Trial Summary

Neoadjuvant chemotherapy is a systemic cytotoxic drug therapy for non-metastatic tumors before local therapy, Now it has become an important part of standard treatment for a stage II, III, and the first clinical Ⅳ breast cancer .Both domestic and foreign authoritative guidelines recommend the use of albumin-binding paclitaxel in the neoadjuvant treatment of breast cancer .In addition, clinical studies at home and abroad have preliminarily confirmed the application value and therapeutic benefit of albumin-binding paclitaxel in breast cancer neoadjuvant therapy, and the toxic and side effects can be tolerated.

Clinical Trial Description

Data were collected on the efficacy and safety of neoadjuvant therapy in patients receiving albumin-binding taxol regimens,Subgroup analysis was performed for different treatment regimens, dosages, molecular subtypes and tumor stages,To further screen the dominant population and the chemotherapy regimen with clinical benefit of albumin paclitaxel, so as to provide evidence-based medical evidence for breast cancer neoadjuvant clinical diagnosis and treatment. ;

Related Conditions & MeSH terms

• Breast Cancer Stage
• Breast Neoplasms

• NCT number: NCT03959397
• Study type: Interventional
• Source: Jilin University
• Contact: Fan zhimin, Doctor
• Phone: 13904321567
• Email: 13364308696@163.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2019
• Completion date: December 1, 2024